Microvesicle

Source: Wikipedia, the free encyclopedia.
(Redirected from
Endothelial microparticle
)
Transmission electron micrograph of lead citrate stained microvesicles. Black bar is 100 nanometers

Microvesicles (ectosomes, or microparticles) are a type of extracellular vesicle (EV) that are released from the cell membrane.[1] In multicellular organisms, microvesicles and other EVs are found both in tissues (in the interstitial space between cells) and in many types of body fluids.[2] Delimited by a phospholipid bilayer,[3][4] microvesicles can be as small as the smallest EVs (30 nm in diameter) or as large as 1000 nm. They are considered to be larger, on average, than intracellularly-generated EVs known as exosomes. Microvesicles play a role in intercellular communication and can transport molecules such as mRNA, miRNA, and proteins between cells.[5]

Though initially dismissed as cellular debris, microvesicles may reflect the antigenic content of the cell of origin and have a role in cell signaling. Like other EVs, they have been implicated in numerous physiologic processes, including anti-tumor effects, tumor immune suppression, metastasis, tumor-stroma interactions, angiogenesis, and tissue regeneration.[6][7][8][9] Microvesicles may also remove misfolded proteins, cytotoxic agents and metabolic waste from the cell. Changes in microvesicle levels may indicate diseases including cancer.[10][11]

Formation and contents

Different cells can release microvesicles from the plasma membrane. Sources of microvesicles include

neutrophils, tumor cells and placenta
.

Platelets play an important role in maintaining hemostasis: they promote

prions and molecules CD41 and CXCR4.[12]

Endothelial microparticles

Endothelial microparticles are small

vesicles that are released from endothelial cells and can be found circulating in the blood.[13]

The microparticle consists of a

plasma membrane surrounding a small amount of cytosol. The membrane of the endothelial microparticle contains receptors and other cell surface molecules which enable the identification of the endothelial origin of the microparticle, and allow it to be distinguished from microparticles from other cells, such as platelets
.

Although circulating endothelial microparticles can be found in the blood of normal individuals, increased numbers of circulating endothelial microparticles have been identified in individuals with certain diseases, including hypertension and cardiovascular disorders,[14] and pre-eclampsia[15] and various forms of vasculitis. The endothelial microparticles in some of these disease states have been shown to have arrays of cell surface molecules reflecting a state of endothelial dysfunction. Therefore, endothelial microparticles may be useful as an indicator or index of the functional state of the endothelium in disease, and may potentially play key roles in the pathogenesis of certain diseases, including rheumatoid arthritis.[16]

Endothelial microparticles have been found to prevent apoptosis in recipient cells by inhibiting the p38 pathway via inactivating mitogen-activated protein kinase (MKP)-1. Uptake of endothelial micoparticles is Annexin I/Phosphatidylserine receptor dependant.[17]

Microparticles are derived from many other cell types.[18]

Process of formation

The process of the formation of exosomes. 1. Cell undergoes endocytosis forming endocytic vesicles. 2. Endocytic vesicles fuse together forming an early endosome. 3. Endocytic cisterna matures into exocytic multivesicular body, during which membrane invaginations form exosomes. 4.Multivesicular body fuses with the plasma membrane, releasing exosomes into the extracellular space.

Microvesicles and exosomes are formed and released by two slightly different mechanisms. These processes result in the release of intercellular signaling vesicles. Microvesicles are small,

plasma membrane-derived particles that are released into the extracellular environment by the outward budding and fission of the plasma membrane. This budding process involves multiple signaling pathways including the elevation of intracellular calcium and reorganization of the cell's structural scaffolding. The formation and release of microvesicles involve contractile machinery that draws opposing membranes together before pinching off the membrane connection and launching the vesicle into the extracellular space.[19][20][21]

Microvesicle budding takes place at unique locations on the cell membrane that are enriched with specific lipids and proteins reflecting their cellular origin. At these locations,

nucleic acids are selectively incorporated into microvesicles and released into the surrounding environment.[20]

Exosomes are membrane-covered vesicles, formed intracellularly are considered to be smaller than 100 nm. In contrast to microvesicles, which are formed through a process of membrane budding, or

multivesicular body (MVB). The MVB containing segregated endosomes ultimately fuses with the plasma membrane, resulting in exocytosis of the exosomes.[21][22]

Once formed, both microvesicles and exosomes (collectively called extracellular vesicles) circulate in the extracellular space near the site of release, where they can be taken up by other cells or gradually deteriorate. In addition, some vesicles migrate significant distances by diffusion, ultimately appearing in biological fluids such as cerebrospinal fluid, blood, and urine.[21]

Mechanism of shedding

There are three mechanisms which lead to release of vesicles into the extracellular space. First of these mechanisms is exocytosis from multivesicular bodies and the formation of exosomes. Another mechanism is budding of microvesicles directly from a plasma membrane. And the last one is cell death leading to apoptotic blebbing. These are all energy-requiring processes.

Under physiologic conditions, the plasma membrane of cells has an asymmetric distribution of

scramblase
, responsible for non-specific redistribution of lipids across the membrane.

After cell stimulation, including apoptosis, a subsequent cytosolic Ca2+ increase promotes the loss of phospholipid asymmetry of the plasma membrane, subsequent phosphatidylserine exposure, and a transient phospholipidic imbalance between the external leaflet at the expense of the inner leaflet, leading to budding of the plasma membrane and microvesicle release.[23]

Molecular contents

The lipid and protein content of microvesicles has been analyzed using various biochemical techniques. Microvesicles display a spectrum of enclosed molecules enclosed within the vesicles and their plasma membranes. Both the membrane molecular pattern and the internal contents of the vesicle depend on the cellular origin and the molecular processes triggering their formation. Because microvesicles are not intact cells, they do not contain

mitochondria, Golgi, endoplasmic reticulum, or a nucleus with its associated DNA.[22][24]

Microvesicle membranes consist mainly of

adaptive immunity, while microvesicles released from tumors contain proapoptotic molecules and oncogenic receptors (e.g. EGFR).[22]

In addition to the proteins specific to the cell type of origin, some proteins are common to most microvesicles. For example, nearly all contain the cytoplasmic proteins tubulin, actin and actin-binding proteins, as well as many proteins involved in signal transduction, cell structure and motility, and transcription. Most microvesicles contain the so-called "heat-shock proteins" hsp70 and hsp90, which can facilitate interactions with cells of the immune system. Finally, tetraspanin proteins, including CD9, CD37, CD63 and CD81 are one of the most abundant protein families found in microvesicle membranes.[22][24][25][26] Many of these proteins may be involved in the sorting and selection of specific cargos to be loaded into the lumen of the microvesicle or its membrane.[27]

Other than lipids and proteins, microvesicles are enriched with nucleic acids (e.g., messenger RNA (

miRNA)). The identification of RNA molecules in microvesicles supports the hypothesis that they are a biological vehicle for the transfer of nucleic acids and subsequently modulate the target cell's protein synthesis. Messenger RNA transported from one cell to another through microvesicles can be translated into proteins, conferring new function to the target cell. The discovery that microvesicles may shuttle specific mRNA and miRNA suggests that this may be a new mechanism of genetic exchange between cells.[26][28] Exosomes produced by cells exposed to oxidative stress can mediate protective signals, reducing oxidative stress in recipient cells, a process which is proposed to depend on exosomal RNA transfer.[29] These RNAs are specifically targeted to microvesicles, in some cases containing detectable levels of RNA that is not found in significant amounts in the donor cell.[26]

Because the specific proteins, mRNAs, and miRNAs in microvesicles are highly variable, it is likely that these molecules are specifically packaged into vesicles using an active sorting mechanism. At this point, it is unclear exactly which mechanisms are involved in packaging soluble proteins and nucleic acids into microvesicles.[20][30]

Role on target cells

Once released from their cell of origin, microvesicles interact specifically with cells they recognize by binding to cell-type specific, membrane-bound receptors. Because microvesicles contain a variety of surface molecules, they provide a mechanism for engaging different cell receptors and exchanging material between cells. This interaction ultimately leads to fusion with the target cell and release of the vesicles' components, thereby transferring bioactive molecules, lipids, genetic material, and proteins. The transfer of microvesicle components includes specific mRNAs and proteins, contributing to the proteomic properties of target cells.[26] microvesicles can also transfer miRNAs that are known to regulate gene expression by altering mRNA turnover.[20][21][24][31]

Mechanisms of signaling

Degradation

In some cases, the degradation of microvesicles is necessary for the release of

growth factors using this mechanism of release.[21]

Fusion

Proteins on the surface of the microvesicle will interact with specific molecules, such as integrin, on the surface of its target cell. Upon binding, the microvesicle can fuse with the plasma membrane. This results in the delivery of nucleotides and soluble proteins into the cytosol of the target cell as well as the integration of lipids and membrane proteins into its plasma membrane.[3]

Internalization

Microvesicles can be endocytosed upon binding to their targets, allowing for additional steps of regulation by the target cell. The microvesicle may fuse, integrating lipids and membrane proteins into the endosome while releasing its contents into the cytoplasm. Alternatively, the endosome may mature into a lysosome causing the degradation of the microvesicle and its contents, in which case the signal is ignored.[3]

Transcytosis

After internalization of microvesicle via endocytosis, the endosome may move across the cell and fuse with the plasma membrane, a process called

blood brain barrier, by moving from cell to cell.[32]

Contact dependent signaling

In this form of signaling, the microvesicle does not fuse with the plasma membrane or engulfed by the target cell. Similar to the other mechanisms of signaling, the microvesicle has molecules on its surface that will interact specifically with its target cell. There are additional surface molecules, however, that can interact with receptor molecules which will interact with various signaling pathways.

MHC molecules on the surface of microvesicle can stimulate an immune response.[27] Alternatively, there may be molecules on microvesicle surfaces that can recruit other proteins to form extracellular protein complexes that may be involved in signaling to the target cell.[21]

Relevance in disease

Cancer

Promoting aggressive tumor phenotypes

The oncogenic receptor ECGFvIII, which is located in a specific type of aggressive glioma tumor, can be transferred to a non-aggressive population of tumor cells via microvesicles. After the oncogenic protein is transferred, the recipient cells become transformed and show characteristic changes in the expression levels of target genes. It is possible that transfer of other mutant oncogenes, such as HER2, may be a general mechanism by which malignant cells cause cancer growth at distant sites.[20][31] Microvesicles from non-cancer cells can signal to cancer cells to become more aggressive. Upon exposure to microvesicles from tumor-associated macrophages, breast cancer cells become more invasive in vitro.[33]

Promoting angiogenesis

Angiogenesis, which is essential for tumor survival and growth, occurs when endothelial cells proliferate to create a matrix of blood vessels that infiltrate the tumor, supplying the nutrients and oxygen necessary for tumor growth. A number of reports have demonstrated that tumor-associated microvesicles release proangiogenic factors that promote endothelial cell proliferation, angiogenesis, and tumor growth. Microvesicles shed by tumor cells and taken up by endothelial cells also facilitate angiogenic effects by transferring specific mRNAs and miRNAs.[21]

Involvement in multidrug resistance

When anticancer drugs such as

chemotherapeutic agents and resulting in significantly increased tumor growth, survival, and metastasis.[20][34]

Interference with antitumor immunity

Microvesicles from various tumor types can express specific cell-surface molecules (e.g. FasL or CD95) that induce

T-cell apoptosis and reduce the effectiveness of other immune cells. microvesicles released from lymphoblastoma cells express the immune-suppressing protein latent membrane protein-1 (LMP1), which inhibits T-cell proliferation and prevents the removal of circulating tumor cells (CTCs). As a consequence, tumor cells can turn off T-cell responses or eliminate the antitumor immune cells altogether by releasing microvesicles.[20]
the combined use of microvesicles and 5-FU resulted in enhanced chemosensitivity of squamous cell carcinoma cells more than the use of either 5-FU or microvesicle alone[35]

Impact on tumor metastasis

Degradation of the extracellular matrix is a critical step in promoting tumor growth and metastasis. Tumor-derived microvesicles often carry protein-degrading enzymes, including matrix metalloproteinase 2 (

MMP-9, and urokinase-type plasminogen activator (uPA). By releasing these proteases, tumor cells can degrade the extracellular matrix and invade surrounding tissues. Likewise, inhibiting MMP-2, MMP-9, and uPA prevents microvesicles from facilitating tumor metastasis. Matrix digestion can also facilitate angiogenesis, which is important for tumor growth and is induced by the horizontal transfer of RNAs from microvesicles.[20]

Cellular Origin of Microvesicles

The release of microvesicles has been shown from endothelial cells,

rheumatic diseases.[21][22]

Cardiovascular disease

Microvesicles are involved in cardiovascular disease initiation and progression. Microparticles derived from monocytes aggravate atherosclerosis by modulating inflammatory cells.[38] Additionally, microvesicles can induce clotting by binding to clotting factors or by inducing the expression of clotting factors in other cells.[39] Circulating microvesicles isolated from cardiac surgery patients were found to be thrombogenic in both in vitro assays and in rats. Microvesicles isolated from healthy individuals did not have the same effects and may actually have a role in reducing clotting.[40][39] Tissue factor, an initiator of coagulation, is found in high levels within microvesicles, indicating their role in clotting.[41] Renal mesangial cells exposed to high glucose media release microvesicles containing tissue factor, having an angiogenic effect on endothelial cells.[42]

Inflammation

Microvesicles contain cytokines that can induce

leukocytes to the area, resulting in the aggregation of cells.[3][43] However, microvesicles also seem to be involved in a normal physiological response to disease, as there are increased levels of microvesicles that result from pathology.[39]

Neurological disorders

Microvesicles seem to be involved in a number of neurological diseases. Since they are involved in numerous vascular diseases and inflammation,

tau proteins during early stage Alzheimer's disease. Similarly, increased levels of CD133 are an indicator of epilepsy.[44]

Clinical applications

Detection of cancer

Tumor-associated microvesicles are abundant in the blood, urine, and other body fluids of patients with cancer, and are likely involved in tumor progression. They offer a unique opportunity to noninvasively access the wealth of biological information related to their cells of origin. The quantity and molecular composition of microvesicles released from

CA-125, and CEA have been used to help diagnose pancreatic, ovarian, and gastrointestinal malignancies, respectively. However, although they have proven clinical utility, none of these tumor markers are highly sensitive or specific. Clinical research data suggest that tumor-specific markers exposed on microvesicles are useful as a clinical tool to diagnose and monitor disease.[46] Research is also ongoing to determine if tumor-specific markers exposed on microvesicles are predictive for therapeutic response.[47][48][49][50]

Evidence produced by independent research groups has demonstrated that microvesicles from the cells of healthy tissues, or selected miRNAs from these microvesicles, can be employed to reverse many tumors in pre-clinical cancer models, and may be used in combination with chemotherapy.[51][52]

Conversely, microvesicles processed from a tumor cell are involved in the transport of cancer proteins and in delivering

dendritic cells
.

Tumor microvesicles also carry tumor

body fluids can be potential markers for tumor diagnostics.[20]

Microvesicles and Rheumatoid arthritis

IL-1
.

Biological markers for disease

In addition to detecting cancer, it is possible to use microvesicles as biological markers to give prognoses for various diseases. Many types of neurological diseases are associated with increased level of specific types of circulating microvesicles. For example, elevated levels of phosphorylated tau proteins can be used to diagnose patients in early stages of Alzheimer's. Additionally, it is possible to detect increased levels of CD133 in microvesicles of patients with epilepsy.[44]

Mechanism for drug delivery

Circulating microvesicles may be useful for the delivery of drugs to very specific targets. Using electroporation or centrifugation to insert drugs into microvesicles targeting specific cells, it is possible to target the drug very efficiently.[32] This targeting can help by reducing necessary doses as well as prevent off-target side effects. They can target anti-inflammatory drugs to specific tissues.[43] Additionally, circulating microvesicles can bypass the blood–brain barrier and deliver their cargo to neurons while not having an effect on muscle cells. The blood-brain barrier is typically a difficult obstacle to overcome when designing drugs, and microvesicles may be a means of overcoming it.[32] Current research is looking into efficiently creating microvesicles synthetically, or isolating them from patient or engineered cell lines.[53]

See also

References

  1. PMID 25979354
    .
  2. PMID 26564379
    .
  3. ^
    PMID 20703216
    .
  4. S2CID 7764903
    .
  5. PMID 21285958
    .
  6. PMID 16453000
    .
  7. PMID 19002258
    .
  8. PMID 20079801
    .
  9. PMID 19155311
    .
  10. S2CID 2746182
    .
  11. PMID 29535851
    .
  12. PMID 18198347
    .
  13. S2CID 8442260
    .
  14. ^ Boulanger, Chantal M (March 2010). "Microparticles, vascular function and hypertension". Current Opinion in Nephrology and Hypertension. 19 (2): 177–180.
    S2CID 38211873
    .
  15. PMID 24319051
    .
  16. ^ Boilard, E.; et al. (January 2010). "Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production". Science. 327 (5965): 580–583.
    PMID 20110505
    .
  17. S2CID 226320
    .
  18. PMID 26596959
    .
  19. ^
    PMID 19687520.[dead link
    ]
  20. ^
    PMID 20445011
    .
  21. ^
    PMID 19144520
    .
  22. ^
    S2CID 23475443
    .
  23. S2CID 20507534
    .
  24. ^
    PMID 18331451
    .
  25. S2CID 660825
    .
  26. ^
    S2CID 8599814
    .
  27. ^
    PMID 23420871
    .
  28. PMID 19266099
    .
  29. ^ Eldh M, Ekström K, Valadi H, Sjöstrand M, Olsson B, Jernås M, Lötvall J. Exosomes Communicate Protective Messages during Oxidative Stress; Possible Role of Exosomal Shuttle RNA. PLoS One. 2010 Dec 17;5(12):e15353.
  30. PMID 19442504
    .
  31. ^
    PMID 16453000
    .
  32. ^
    S2CID 20386810
    .
  33. PMID 21939504
    .
  34. PMID 12907600
    .
  35. ^ Ghada A. Abd El Latif , Iman M. Aboushady and Dina Sabry Decreased VEGF and cyclin D1 genes expression enhances chemosensitivity of human squamous cell carcinoma cells to 5-fluorouracil and/or mesenchymal stem cells-derived microvesicles E.D.J. Vol. 65, 2, Pp 1217-1228 ; 2019. DOI: 10.21608/EDJ.2019.72197
  36. ISBN 978-0123878373
    .
  37. PMID 12909311
    .
  38. PMID 22697268
    .
  39. ^
    PMID 16255015
    .
  40. S2CID 22275556
    .
  41. S2CID 18415836
    .
  42. S2CID 207728332
    .
  43. ^
    PMID 20571541
    .
  44. ^
    PMID 22479250
    .
  45. PMID 32284825
    .
  46. S2CID 4876604
    .
  47. S2CID 29689761
    .
  48. ^ Pawlowski, Traci L.; Spetzler, David; Tinder, Teresa; Esmay, Paula; Conrad, Amber; Ellis, Phil; Kennedy, Patrick; Tyrell, Annemarie; et al. (April 20, 2010). Identifying and characterizing subpopulation of exosomes to provide the foundation for a novel exosome-based cancer diagnostic platform. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research.
  49. doi:10.1200/jco.2010.28.15_suppl.4636.[permanent dead link
    ]
  50. ^ Kuslich, Christine; Pawlowski, Traci; Kimbrough, Jeff; Deng, Ta; Tinder, Teresa; Kim, Joon; Spetzler, David (April 18, 2010). Plasma exosomes are a robust biosignature for prostate cancer. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Also published as Kuslich, Christine; Pawlowski, Traci; Kimbrough, Jeff; Deng, Ta; Tinder, Teresa; Kim, Joon; Spetzler, David (2010). "Circulating exosomes are a robust biosignature for prostate cancer" (PDF). Caris Life Sciences. Archived from the original (PDF) on 2016-03-04. Retrieved 2017-11-07.
  51. ^ Microvesicles (MVS) Derived From Adult Stem Cells For Use In The Therapeutic Treatment of a Tumor Disease. PCT/EP2011/052945 Available online
  52. ^ Human Liver Stem Cell-Derived Microvesicles Inhibit Hepatoma Growth in SCID Mice by Delivering Antitumor MicroRNAs. Camussi et al; Stem Cells [2012,30]Available online
  53. ^ "CORDIS | European Commission". Archived from the original on 2008-03-28. Retrieved 2017-11-07.

Further reading

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Microvesicle&oldid=1215825028#Endothelial_microparticles"